Theravance Biopharma (TBPH) Q1 2024 Earnings
TBPH·Reported May 13, 2024·After market close
Theravance Biopharma reported Q1 2024 revenue of $14.5M, beat analyst consensus of $14.0M by $543.0K. Diluted EPS came in at $-0.09, beat the $-0.19 consensus by $0.10.
Revenue
$14.5Mbeat by $543.0K
Consensus: $14.0MDiluted EPS
$-0.09beat by $0.10
Consensus: $-0.19
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Theravance Biopharma's Q1 2024 earnings report.
Theravance Biopharma (TBPH) reported Q1 2024 earnings on May 13, 2024 after market close.
Theravance Biopharma reported revenue of $14.5M and diluted EPS of $-0.09 for Q1 2024.
Revenue beat the consensus estimate of $14.0M by $543.0K. EPS beat the consensus estimate of $-0.19 by $0.10.
You can read the 10-Q periodic report (0001558370-24-008201) directly on SEC EDGAR. The filing index links above go to sec.gov.